Limited short-term effects on human prostate cancer xenograft growth and epidermal growth factor receptor gene expression by the ghrelin receptor antagonist [D-Lys³]-GHRP-6.

Maugham ML, Seim I, Thomas PB, Crisp GJ, Shah ET, Herington AC, Gregory LS, Nelson CC, Jeffery PL, Chopin LK

Endocrine2 Nov 2018Cited by 3 (Europe PMC)

PMID30390209DOI10.1007/s12020-018-1796-9PepBankPUB-30390209

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In NOD/SCID mice with PC3 xenografts, daily D-Lys-GHRP‑6 reduced tumour volume after two weeks.
In plain wordsIn mice with prostate cancer xenografts, D-Lys-GHRP‑6 reduced tumour volume after two weeks.
Peptide
GHRP-6
Outcome
DecreaseTumour volume
Study
mousen: not reported in source
NOD/SCID mice bearing PC3 prostate cancer xenografts
Outcome group
Tumor growth · Cancer
Source sentences
Summary
We demonstrate here that daily intraperitoneal injection of 20 nmoles/mouse [D-Lys³]-GHRP-6 reduces PC3 prostate cancer xenograft tumour volume and weight in NOD/SCID mice at two weeks post treatment initiation.
1 context sentence(design, population, supporting numbers)
Summary · context
NOD/SCID mice with PC3 prostate cancer xenografts were administered 20 nmoles/mouse [D-Lys³]-GHRP-6 daily by intraperitoneal injection for 14 days and tumour volume and weight were measured.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3039020901
02AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In NOD/SCID mice with PC3 xenografts, daily D-Lys-GHRP‑6 reduced tumour weight after two weeks.
In plain wordsIn mice with prostate cancer xenografts, D-Lys-GHRP‑6 reduced tumour weight after two weeks.
Peptide
GHRP-6
Outcome
DecreaseTumour weight
Study
mousen: not reported in source
NOD/SCID mice bearing PC3 prostate cancer xenografts
Outcome group
Tumor growth · Cancer
Source sentences
Summary
We demonstrate here that daily intraperitoneal injection of 20 nmoles/mouse [D-Lys³]-GHRP-6 reduces PC3 prostate cancer xenograft tumour volume and weight in NOD/SCID mice at two weeks post treatment initiation.
1 context sentence(design, population, supporting numbers)
Summary · context
NOD/SCID mice with PC3 prostate cancer xenografts were administered 20 nmoles/mouse [D-Lys³]-GHRP-6 daily by intraperitoneal injection for 14 days and tumour volume and weight were measured.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3039020902
03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In mouse PC3 xenografts treated with D-Lys-GHRP‑6, RNA sequencing showed reduced EGFR expression.
In plain wordsIn mouse prostate cancer xenografts, D-Lys-GHRP‑6 treatment reduced EGFR gene expression.
Peptide
GHRP-6
Outcome
DecreaseTumour EGFR expression
Study
mousen: not reported in source
NOD/SCID mice bearing PC3 prostate cancer xenografts
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
RNA-sequencing revealed reduced expression of epidermal growth factor receptor (EGFR) in these tumours.
1 context sentence(design, population, supporting numbers)
Summary · context
NOD/SCID mice with PC3 prostate cancer xenografts were administered 20 nmoles/mouse [D-Lys³]-GHRP-6 daily by intraperitoneal injection for 14 days and tumour volume and weight were measured.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3039020903
04AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In mice with PC3 xenografts, D-Lys-GHRP‑6 effects were transitory and were lost after 18 days of treatment.
In plain wordsIn mice with prostate cancer xenografts, D-Lys-GHRP‑6 effects disappeared after 18 days of treatment.
Peptide
GHRP-6
Outcome
No significant changePersistence of antitumour effects
Study
mousen: not reported in source
NOD/SCID mice bearing PC3 prostate cancer xenografts
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Further experiments demonstrated that the effects of [D-Lys³]-GHRP-6 are transitory and lost after 18 days of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
NOD/SCID mice with PC3 prostate cancer xenografts were administered 20 nmoles/mouse [D-Lys³]-GHRP-6 daily by intraperitoneal injection for 14 days and tumour volume and weight were measured.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3039020904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.